Apocrine skin appendage carcinoma. Real clinical practice


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Skin appendage tumors are a large group of neoplasms, the morphological source of which is the sweat glands or the pilosebaceous unit of the skin (cells of the hair follicle, sebaceous and apocrine glands). The origin of these neoplasms can be both sporadic and genetically determined. To date, the method of choice for treatment remains a wide excision of the skin tumor (the distance from the edge of the resection should be 1-2 cm) with lymphadenectomy with cytologically verified metastasis to the lymph node. The use of drug treatment remains controversial. In routine practice, adjuvant chemotherapy (CT) is not used due to the resistance of the tumor to CT. However, cases of favorable tumor responses to various chemotherapy regimens have been described in patients with metastatic form of primary apocrine carcinoma, which undoubtedly requires further study of the issue of chemotherapy. The article presents a clinical case of patient G. born in 1947 with a diagnosis of apocrine skin appendage carcinoma at the right axillary region.

Full Text

Restricted Access

About the authors

Yulia V. Vakhabova

European Medical Center

Email: alt78@yandex.ru
Cand. Sci. (Med.), Chemotherapist, Department of Oncology and Hematology 35, Schepkina str., Moscow 129090, Russian Federation

M. A Polyak

P.A. Hertsen Moscow Oncology Research Institute, Branch of the National Medical Research Radiological Center

Moscow, Russia

E. O Ignatova

Blokhin National Medical Research Center of Oncology

Moscow, Russia

V. A Derzhavin

P.A. Hertsen Moscow Oncology Research Institute, Branch of the National Medical Research Radiological Center

Moscow, Russia

O. A Anurova

P.A. Hertsen Moscow Oncology Research Institute, Branch of the National Medical Research Radiological Center

Moscow, Russia

D. V Kalinin

Vishnevsky National Medical Research Center for Surgery

Moscow, Russia

V. K Tokaev

P.A. Hertsen Moscow Oncology Research Institute, Branch of the National Medical Research Radiological Center

Moscow, Russia

E. A Troshenkov

P.A. Hertsen Moscow Oncology Research Institute, Branch of the National Medical Research Radiological Center

Moscow, Russia

References

  1. Kazakov D.V., McKee PH., MichalM., Kacerovska D. Cutaneous Adnexal Tumors, 1 st ed. Lippincott Williams and Wilkins Health, Philadelphia; 2012.
  2. Lee DA, Grossman M.E., Schneiderman P CelebiJ.T. Genetics of skin appendage neoplasms and related syndromes. J Med Genet. 2005;42(11):811-19. doi: 10.1136/jmg.2004.025577.
  3. Martinez S.R., Barr K.L., Canter R.J. Rare tumors through the looking glass: an examination of malignant cutaneous adnexal tumors. Arch Dermatol. 2011; 47:1058. Doi: 10.1001/ archdermatol.2011.229.
  4. Guardoli D, Argenziano G., Ponti G., et al. A novel CYLD germline mutation in Brooke-Spiegler syndrome. J Eur Acad Dermatol Venerol. 2015;29:457-62. doi: 10.1111/jdv.12578.
  5. Harms P.W., Hovelson D.H., Cani A.K., et al. Porocarcinomas harbor recurrent HRAS-activating mutations and tumor suppressor inactivating mutations. Hum Pathol. 2016;51:25-31. doi: 10.1016/j.humpath.2015.12.015.
  6. Sekine S., et al. Recurrent YAP1-MAML2 and YAP1-NUTM1 fusions in poroma and porocarcinoma //The Journal of clinical investigation. 2019;129(9):3827-32. doi: 10.1172/JCI126185.
  7. Маникайло А.Е., Гуторов С.Л. Таргетная терапия аденокистозного рака пищевода. Сборник научных трудов XXXX юбилейной Итоговой научной конференции Общества молодых ученых МГМСУ им. А.И. Евдокимова 2018. С. 264-65
  8. Bell D., et al. Next-generation sequencing reveals rare genomic alterations in aggressive digital papillary adenocarcinoma.Annals of diagnostic pathology. 2015;19(6):381-84. Doi: 10.1016 / j.anndiagpath.2015.08.002.
  9. BrichkovI., Daskalakis T., Rankin L., Divino C. Sweat gland carcinoma. Am Surg. 2004;70:63-6.
  10. Hollowell K.L., Agle S.C., Zervos E.E., Fitzgerald T.L. Cutaneous apocrine adenocarcinoma: defining epidemiology, outcomes, and optimal therapy for a rare neoplasm. J Surg Oncol. 2012;105:415-19. doi: 10.1002/jso.22023.
  11. Vucinic I., Stojadinovic T., Boric Mikez Z., et al. Apocrine carcinoma of the scalp with aggressive clinical course-a case report and review of the literature. CollAntropol. 2013;36:209-12.
  12. Pucevich B, Catinchi-Jaime S., Ho J., Jukic D.M. Invasive primary ductal apocrine adenocarcinoma of axilla: a case report with immunohistochemical profiling and a review of literature. Dermatol Online J. 2008;14:5.
  13. Chintamani, Sharma R., Badran R., et al. Metastatic sweat gland adenocarcinoma: a clinico-pathological dilemma. World J Surg Oncol. 2003;1:13. doi: 10.1186/1477-7819-1-13.
  14. Karaca S., Kulac M., Sahin O., et al. A rare cutaneous tumor of the axilla: apocrine adenocarcinoma. Indian J Dermatol. 2007;52:50. doi: 10.4103/0019-5154.31926.
  15. Chamberlain R.S., Huber K., White J.C., Travaglino-Parda R. Apocrine gland carcinoma of the axilla: review of the literature and recommendations for treatment. Am J Clin Oncol. 1999;22:131-35. doi: 10.1186/s1295 7-015-04 73-1.
  16. Bogner PN., Fullen D.R., Lowe L., et al. Lymphatic mapping and sentinel lymph node biopsy in the detection of early metastasis from sweat gland carcinoma. Cancer 2003;97:2285-89. doi: 10.1002/cncr.11328.
  17. Hernandez J.M., Copeland E.M. Infiltrating apocrine adenocarcinoma with extramammary pagetoid spread. Am Surg. 2007;73:307-9.
  18. Morabito A., Bevilacqua P, Vitale S., et al. Clinical management of a case of recurrent apocrine gland carcinoma of the scalp: efficacy of a chemotherapy schedule with methotrexate and bleomycin. Tumori. 2000;86:472-74.
  19. Mezger J., Remberger K., Schalhorn A., et al. Treatment of metastatic sweat gland carcinoma by a four drug combination chemotherapy: response in two cases. Med Oncol Tumor Pharmacother. 1986;3:29-34. doi: 10.1007/BF02934573.
  20. Bellman B., Gregory N.A., Silvers D., Fountain K.S. Sweat gland carcinoma with metastases to the skin: response to 5-fluorouracil chemotherapy Cutis. 1995;55:221-24.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies